Cardiac function in 5-year survivors of childhood cancer: A long-term follow-up study

Helena J. Van Der Pal, Elvira C. Van Dalen, Michael Hauptmann, Wouter E. Kok, Huib N. Caron, Cor Van Den Bos, Foppe Oldenburger, Caro C. Koning, Flora E. Van Leeuwen, Leontien C. Kremer

Research output: Contribution to journalArticlepeer-review

165 Citations (Scopus)

Abstract

Background: Childhood cancer survivors (CCSs) have an increased risk of morbidity and mortality. We evaluated the prevalence and determinants of left ventricular (LV) dysfunction in a large cohort of long-term CCSs treated with different potentially cardiotoxic therapies. Methods: The study cohort consisted of all adult 5-year CCSs who were treated with potentially cardiotoxic therapies and who visited our late effects outpatient clinic. Echocardiography was performed in patients who had received anthracyclines, cardiac irradiation, high-dose cyclophosphamide, or high-dose ifosfamide. Detailed treatment data were registered. Both multivariate linear and logistic regression analyses were performed. Results: Of 601 eligible CCSs, 525 (87%) had an echocardiogram performed, of which 514 were evaluable for assessment of the LV shortening fraction (LVSF). The median overall LVSF in the whole group of CCSs was 33.1% (range, 13.0%-56.0%). Subclinical cardiac dysfunction (LVSF<30%) was identified in 139 patients (27%). In a multivariate linear regression model, LVSF was reduced with younger age at diagnosis, higher cumulative anthracycline dose, and radiation to the thorax. High-dose cyclophosphamide and ifosfamide were not associated with a reduction of LVSF. Vincristine sulfate was associated with a nonsignificant decrease of cardiac function (P=.07). Epirubicin hydrochloride was as cardiotoxic as doxorubicin when corrected for tumor efficacy, and daunorubicin hydrochloride seemed less cardiotoxic. Conclusions: A high percentage (27%) of young adult CCSs have an abnormal cardiac function. The strongest predictors of subclinical cardiac dysfunction are anthracycline dose, cardiac irradiation, and younger age at diagnosis. There is a suggestion that daunorubicin is less cardiotoxic than other anthracyclines.

Original languageEnglish
Pages (from-to)1247-1255
Number of pages9
JournalArchives of Internal Medicine
Volume170
Issue number14
DOIs
Publication statusPublished - 26 Jul 2010
Externally publishedYes

Fingerprint

Dive into the research topics of 'Cardiac function in 5-year survivors of childhood cancer: A long-term follow-up study'. Together they form a unique fingerprint.

Cite this